- Home
- PTC vs JAZZ Comparison
PTC vs JAZZ Comparison
Compare PTC & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTC | JAZZ |
|---|---|---|
| Founded | 1985 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 16.1B |
| IPO Year | 1995 | 2007 |
Fundamental Metrics
Financial Performance| Metric | PTC | JAZZ |
|---|---|---|
| Price | $194.20 | $212.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 22 |
| Target Price | $201.00 | ★ $294.64 |
| AVG Volume (30 Days) | ★ 4.1M | 713.1K |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.87 | N/A |
| EPS | ★ 7.43 | 7.17 |
| Revenue | ★ $2,739,226,000.00 | $1,618,693,000.00 |
| Revenue This Year | N/A | $10.65 |
| Revenue Next Year | $6.37 | $5.76 |
| P/E Ratio | ★ $26.00 | $29.78 |
| Revenue Growth | ★ 19.18 | N/A |
| 52 Week Low | $108.50 | $128.80 |
| 52 Week High | $206.57 | $266.38 |
Technical Indicators
Market Signals| Indicator | PTC | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 80.26 | 33.56 |
| Support Level | $131.90 | $194.77 |
| Resistance Level | $195.52 | $241.39 |
| Average True Range (ATR) | 1.58 | 6.97 |
| MACD | 0.66 | -0.83 |
| Stochastic Oscillator | 96.48 | 16.51 |
Price Performance
Historical ComparisonAbout PTC PTC Inc.
PTC is a US-based global company that offers high-end computer-assisted design, product lifecycle management, and augmented reality solutions that industrial manufacturers commonly use on factory floors. Founded in 1985, PTC is a major player in parametric design and serves some of the world's most well-known equipment manufacturers, such as Caterpillar, Garmin, and Thermo Fisher.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.